Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences
January 07, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Fourth Quarter and Full Year 2019 Results
March 12, 2020 07:01 ET
|
Trevena Inc.
PDUFA date of August 7, 2020 for IV oliceridine; FDA considers NDA resubmission complete Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734) Announces NIH...
Trevena to Report Fourth Quarter and Full Year 2019 Results on March 12, 2020
March 05, 2020 17:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Appoints Scott Applebaum as Chief Legal and Compliance Officer and SVP of Regulatory Affairs
February 13, 2020 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Present at the 2019 Cantor Global Healthcare Conference
September 27, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...